MA43032A - Inhibiteurs isoindolinone de l'interaction mdm2-p53 ayant une activité anticancéreuse - Google Patents
Inhibiteurs isoindolinone de l'interaction mdm2-p53 ayant une activité anticancéreuseInfo
- Publication number
- MA43032A MA43032A MA043032A MA43032A MA43032A MA 43032 A MA43032 A MA 43032A MA 043032 A MA043032 A MA 043032A MA 43032 A MA43032 A MA 43032A MA 43032 A MA43032 A MA 43032A
- Authority
- MA
- Morocco
- Prior art keywords
- mdm2
- interaction
- cancer activity
- isoindolinone
- inhibitors
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1517217.4A GB201517217D0 (en) | 2015-09-29 | 2015-09-29 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43032A true MA43032A (fr) | 2018-08-08 |
Family
ID=54544291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043032A MA43032A (fr) | 2015-09-29 | 2016-09-29 | Inhibiteurs isoindolinone de l'interaction mdm2-p53 ayant une activité anticancéreuse |
Country Status (28)
Country | Link |
---|---|
US (3) | US10544132B2 (fr) |
EP (2) | EP4151633A1 (fr) |
JP (2) | JP7029387B2 (fr) |
KR (1) | KR20180081706A (fr) |
CN (2) | CN115572252A (fr) |
AU (2) | AU2016330030C1 (fr) |
BR (1) | BR112018005932B1 (fr) |
CA (1) | CA2999400A1 (fr) |
DK (1) | DK3356350T3 (fr) |
ES (1) | ES2934181T3 (fr) |
FI (1) | FI3356350T3 (fr) |
GB (1) | GB201517217D0 (fr) |
HK (1) | HK1250715A1 (fr) |
HR (1) | HRP20221487T1 (fr) |
HU (1) | HUE060638T2 (fr) |
IL (1) | IL258213B (fr) |
LT (1) | LT3356350T (fr) |
MA (1) | MA43032A (fr) |
MX (1) | MX2018004008A (fr) |
NZ (1) | NZ780787A (fr) |
PH (1) | PH12018500610B1 (fr) |
PL (1) | PL3356350T3 (fr) |
PT (1) | PT3356350T (fr) |
SA (1) | SA518391218B1 (fr) |
SG (1) | SG10201912833XA (fr) |
SI (1) | SI3356350T1 (fr) |
TW (1) | TWI761315B (fr) |
WO (1) | WO2017055860A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
WO2018054782A1 (fr) * | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de la pi3k |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704965D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CN107118183B (zh) * | 2017-05-17 | 2021-02-02 | 成都化润药业有限公司 | 一种四氢-3-呋喃甲醇的合成方法 |
WO2019061324A1 (fr) | 2017-09-29 | 2019-04-04 | Curis Inc. | Formes cristallines d'immunomodulateurs |
SG11202003081WA (en) | 2017-10-11 | 2020-05-28 | Aurigene Discovery Tech Ltd | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
WO2019087092A1 (fr) | 2017-11-06 | 2019-05-09 | Aurigene Discovery Technologies Limited | Thérapies conjointes à des fins d'immunomodulation |
CN111868088A (zh) * | 2018-03-20 | 2020-10-30 | 诺华股份有限公司 | 药物组合 |
CN110194760B (zh) * | 2019-05-27 | 2021-08-17 | 浙江农林大学暨阳学院 | 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法 |
CN113544130B (zh) * | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
EP4143196A4 (fr) * | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | INHIBITEURS DE PI3K-a ET PROCÉDÉ D'UTILISATION DE CEUX-CI |
US20230313313A1 (en) | 2020-08-27 | 2023-10-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
WO2023098880A1 (fr) * | 2021-12-02 | 2023-06-08 | 上海翰森生物医药科技有限公司 | Dérivé de cycle fusionné, son procédé de préparation et son application |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH374071A (de) | 1959-04-30 | 1963-12-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Isoindolinderivaten |
US3466298A (en) | 1967-03-14 | 1969-09-09 | American Home Prod | Process for the preparation of 2-(2-aminoethyl)isoindolines |
US3763178A (en) | 1968-09-05 | 1973-10-02 | American Home Prod | Imidazolinyl phenyl carbonyl acid addition salts and related compounds |
GB1325066A (en) | 1970-02-12 | 1973-08-01 | American Home Prod | Phthalimidine compounds |
AR203996A1 (es) | 1972-03-16 | 1975-11-12 | Rhone Poulenc Sa | Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1 |
FR2217000B1 (fr) | 1973-02-08 | 1976-04-09 | Rhone Poulenc Ind | |
GB1601701A (en) | 1977-07-22 | 1981-11-04 | Delmar Chem | Production of heterocyclic benzamide compounds |
US4200759A (en) | 1978-07-20 | 1980-04-29 | Delmar Chemicals, Limited | Preparation of imidazo[2,1-a]isoindole compounds |
US4244966A (en) | 1979-09-24 | 1981-01-13 | American Home Products Corporation | 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives |
US4312809A (en) | 1980-10-31 | 1982-01-26 | E. R. Squibb & Sons, Inc. | Lactam derivatives of mercaptoacylamino acids |
US4331600A (en) | 1980-10-31 | 1982-05-25 | Usv Pharmaceutical Corporation | Intermediates for the synthesis of phthalimidines |
FR2533563A1 (fr) | 1982-09-23 | 1984-03-30 | Adir | Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
HU212435B (en) | 1990-06-07 | 1996-06-28 | Sandoz Ag | Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients. |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
WO1998004689A1 (fr) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate |
TW448172B (en) | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
DE19807423A1 (de) | 1998-02-21 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln |
EP1199306B1 (fr) | 1999-07-26 | 2005-12-07 | Banyu Pharmaceutical Co., Ltd. | Derives de biaryluree |
AU1466001A (en) | 1999-11-05 | 2001-05-14 | Phase-1 Molecular Toxicology | Methods of determining individual hypersensitivity to an agent |
DE10134482A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
KR20060096513A (ko) | 2001-12-18 | 2006-09-11 | 에프. 호프만-라 로슈 아게 | 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도 |
FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
CN100548980C (zh) | 2002-11-26 | 2009-10-14 | 丸石制药株式会社 | 异吲哚啉衍生物 |
JP2004217591A (ja) | 2003-01-16 | 2004-08-05 | Dai Ichi Seiyaku Co Ltd | シス選択的フルオロシクロプロパン誘導体の製造方法 |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
JP2005255660A (ja) | 2004-03-10 | 2005-09-22 | Katsuhiko Tomooka | 多官能基を有するラクタム類とその製法 |
JPWO2005095341A1 (ja) | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | 含窒素複素環化合物 |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
CN102627649B (zh) | 2005-02-22 | 2015-03-25 | 密执安州立大学董事会 | Mdm2的小分子抑制剂以及其应用 |
US7705021B2 (en) * | 2005-05-02 | 2010-04-27 | Fox Chase Cancer Center | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer |
WO2007021308A1 (fr) | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Isoindolones potentiateurs du récepteur glutamate métabotropique |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2108642A1 (fr) | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Inhibiteurs de jak |
GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
KR20100033981A (ko) | 2007-06-03 | 2010-03-31 | 벤더르빌트 유니버시티 | 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법 |
US20090156735A1 (en) * | 2007-12-14 | 2009-06-18 | General Electric Company | Composition, article, and associated method |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
DK2340021T3 (da) | 2008-09-18 | 2012-12-10 | Hoffmann La Roche | Substituerede pyrrolidin-2-carboxamider |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
CN102712650B (zh) | 2009-11-12 | 2015-05-20 | 密歇根大学董事会 | 螺-吲哚酮mdm2拮抗剂 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
CA2829188C (fr) | 2011-03-10 | 2016-10-18 | Daiichi Sankyo Company, Limited | Derive de dispiropyrrolidine |
EP2721007B1 (fr) | 2011-06-20 | 2015-04-29 | Novartis AG | Composés de cyclohexyl-isoquinolinone |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
KR101401705B1 (ko) | 2012-01-31 | 2014-06-27 | 울산대학교 산학협력단 | 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법 |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2838898B1 (fr) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales |
HUE048584T2 (hu) | 2012-10-30 | 2020-08-28 | Mei Pharma Inc | Kombinációs terápiák kemorezisztens rákok kezelésére |
KR101879926B1 (ko) | 2013-07-03 | 2018-08-16 | 에프. 호프만-라 로슈 아게 | MDM2 길항제를 사용한 환자 암 치료를 개인화하기 위한 mRNA-기반 유전자 발현 |
WO2015108175A1 (fr) | 2014-01-14 | 2015-07-23 | Daiichi Sankyo Company, Limited | Signatures géniques associées à la sensibilité aux inhibiteurs de mdm2 |
EP3131544B1 (fr) | 2014-04-17 | 2018-12-12 | The Regents of the University of Michigan | Inhibiteurs de mdm2 et méthodes thérapeutiques les utilisant |
US20170283885A1 (en) | 2014-10-09 | 2017-10-05 | Daiichi Sankyo Company, Limited | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors |
US20160108405A1 (en) | 2014-10-17 | 2016-04-21 | Biomirna Holdings Ltd | Lung cancer diagnostics and therapeutics with mir-660 |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
PT3365334T (pt) | 2015-10-21 | 2024-10-21 | Otsuka Pharma Co Ltd | Compostos benzolactamas como inibidores de proteína quinase |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CA3050645A1 (fr) | 2018-07-27 | 2020-01-27 | Ottawa Hospital Research Institute | Traitement de la leucemie myeloblastique aigue |
US20210311020A1 (en) | 2019-02-24 | 2021-10-07 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
US20230313313A1 (en) | 2020-08-27 | 2023-10-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2015
- 2015-09-29 GB GBGB1517217.4A patent/GB201517217D0/en not_active Ceased
-
2016
- 2016-09-29 LT LTEPPCT/GB2016/053042T patent/LT3356350T/lt unknown
- 2016-09-29 HU HUE16777770A patent/HUE060638T2/hu unknown
- 2016-09-29 ES ES16777770T patent/ES2934181T3/es active Active
- 2016-09-29 MA MA043032A patent/MA43032A/fr unknown
- 2016-09-29 MX MX2018004008A patent/MX2018004008A/es unknown
- 2016-09-29 EP EP22200147.1A patent/EP4151633A1/fr active Pending
- 2016-09-29 US US15/763,698 patent/US10544132B2/en active Active
- 2016-09-29 CN CN202211044004.0A patent/CN115572252A/zh active Pending
- 2016-09-29 CA CA2999400A patent/CA2999400A1/fr active Pending
- 2016-09-29 EP EP16777770.5A patent/EP3356350B1/fr active Active
- 2016-09-29 DK DK16777770.5T patent/DK3356350T3/da active
- 2016-09-29 TW TW105131385A patent/TWI761315B/zh active
- 2016-09-29 BR BR112018005932-3A patent/BR112018005932B1/pt active IP Right Grant
- 2016-09-29 JP JP2018515229A patent/JP7029387B2/ja active Active
- 2016-09-29 NZ NZ780787A patent/NZ780787A/en active IP Right Revival
- 2016-09-29 PT PT167777705T patent/PT3356350T/pt unknown
- 2016-09-29 WO PCT/GB2016/053042 patent/WO2017055860A1/fr active Application Filing
- 2016-09-29 KR KR1020187008605A patent/KR20180081706A/ko not_active Application Discontinuation
- 2016-09-29 PL PL16777770.5T patent/PL3356350T3/pl unknown
- 2016-09-29 HR HRP20221487TT patent/HRP20221487T1/hr unknown
- 2016-09-29 FI FIEP16777770.5T patent/FI3356350T3/fi active
- 2016-09-29 CN CN201680056529.2A patent/CN108290871B/zh active Active
- 2016-09-29 SG SG10201912833XA patent/SG10201912833XA/en unknown
- 2016-09-29 AU AU2016330030A patent/AU2016330030C1/en active Active
- 2016-09-29 PH PH1/2018/500610A patent/PH12018500610B1/en unknown
- 2016-09-29 SI SI201631642T patent/SI3356350T1/sl unknown
-
2018
- 2018-03-19 IL IL258213A patent/IL258213B/en unknown
- 2018-03-28 SA SA518391218A patent/SA518391218B1/ar unknown
- 2018-08-09 HK HK18110249.8A patent/HK1250715A1/zh unknown
-
2019
- 2019-08-08 US US16/535,931 patent/US10981898B2/en active Active
-
2021
- 2021-02-01 US US17/164,045 patent/US12071429B2/en active Active
- 2021-05-10 AU AU2021202962A patent/AU2021202962C1/en active Active
-
2022
- 2022-02-18 JP JP2022024315A patent/JP7566806B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43032A (fr) | Inhibiteurs isoindolinone de l'interaction mdm2-p53 ayant une activité anticancéreuse | |
MA43031A (fr) | Inhibiteurs d'isoindolinone de l'interaction mdm2-p53 ayant une activité anticancéreuse | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
PT3274370T (pt) | Anticorpos anti-ceacam6 e utilizações dos mesmos | |
DK3240773T3 (da) | Picolinamidforbindelser med fungicid aktivitet | |
EP2953958A4 (fr) | Amorces d'amplification d'acides nucléiques très sélectives | |
PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
EP3757228C0 (fr) | Détection multiplex d'acides nucléiques | |
EP2964221A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine | |
DK3145420T3 (da) | Intraoperativ fremgangsmåde til tracking | |
EP2846784A4 (fr) | Composés utiles pour stimuler la dégradation des protéines et procédés utilisant ceux-ci | |
EP2964222A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine | |
EP2964220A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine | |
DK3377484T3 (da) | Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet | |
EP3406336A4 (fr) | Nanofeuille de type structure c ur-écorce | |
PL3411473T3 (pl) | Mezenchymalne komórki macierzyste nasilające aktywność antynowotworową immunoterapii | |
LT3191514T (lt) | Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą | |
CL2016000616A1 (es) | Compuestos heterocíclicos de n-acilimino. | |
EP3387469A4 (fr) | Détermination d'électrofaciès | |
ME03636B (fr) | Composés oxa-diazaspiro ayant une activité contre la douleur | |
DK3484852T3 (da) | Benzo-n-hydroxyamidforbindelser med antitumor-aktivitet | |
FR3033711B3 (fr) | Structure d'assemblage pour piste-jouet | |
DK3335729T3 (da) | Etanercept-sammensætning med forbedret stabilitet | |
ITUB20152292A1 (it) | Accorgimenti per incastonare pietre e solitari. |